This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
bluebird bio Crecimiento futuro
Future controles de criterios 2/6
Se prevé que los ingresos de bluebird bio aumenten en un 21.9% al año. Se prevé que el BPA aumente en un 59.6% al año.
Información clave
n/a
Tasa de crecimiento de los beneficios
59.56%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.3% |
| Tasa de crecimiento de los ingresos | 21.9% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 16 May 2025 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • May 25
High Noon For bluebird
Summary bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival bidder, Ayrmid, previously offered $4.50 plus the same CVR, but financing delays stalled a superior deal. If Ayrmid returns with a $6.50 all-cash offer before Tuesday, shareholders could see a bidding war; time is critical. At ~$5 per share, risk/reward is highly asymmetric—downside is limited, upside could be significant if a bidding war emerges. Read the full article on Seeking Alpha
Nueva narrativa • Apr 08
Patient Starts And Capacity Expansion Will Achieve Breakeven
Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.Artículo de análisis • Jan 04
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%
bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders won't be pleased to see that the share price has had a very rough...Artículo de análisis • Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 1.3x bluebird bio, Inc. ( NASDAQ:BLUE ) may be sending very bullish signals...Seeking Alpha • Sep 26
bluebird bio: Scientific Success And Financial Success, And The Gap Between
Summary Back in 2019 and early 2020, bluebird bio stock was between $40 and $50 a share, and the latest quote is 48 cents. This despite getting three gene therapies on the market. Two of bluebird bio’s gene therapies, Zentego and Lyfgenia, compete with Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, which is approved for basically the same patient populations. The company is cutting staff, especially in R&D, in order to focus on commercial operations. But whether that will work is unknown. Read the full article on Seeking AlphaSeeking Alpha • Jun 27
bluebird bio's Flight Through Financial Fog And Fierce Rivals
Summary bluebird bio, Inc. stock plummeted by 73% amid financial struggles and operational hurdles post FDA approval of their gene therapy Lyfgenia. The company faces intense competition from CRISPR Therapeutics' Casgevy, which benefits from stronger resources and a faster market rollout. Recent financial disclosures are incomplete, obscuring a clear view of bluebird's financial health and prolonging investor uncertainty. Maintain a sell recommendation on bluebird bio due to substantial financial and operational risks, with a cautious note on potential high volatility. Read the full article on Seeking AlphaSeeking Alpha • Mar 23
bluebird bio Is Priced Below IP Value
Summary bluebird bio's stock price has dropped 64% due to safety warnings and high pricing for their sickle cell treatment. The company's intellectual property alone suggests a potential sale value of $300-320 million, higher than its current market cap of $280 million. bluebird bio has extended its cash runway and has the potential to achieve profitability within the next year. Read the full article on Seeking AlphaSeeking Alpha • Jan 25
Bluebird Bio: Innovative Therapies, Monetary Setbacks
Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsourced production, long-term follow-up studies, and intensifying competition are all factors that obscure BLUE's path to profitability. Read the full article on Seeking AlphaArtículo de análisis • Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Artículo de análisis • Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Oct 04
Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Real Endpoints said it is collaboration with bluebird bio (NASDAQ:BLUE) to provide multiple health plans with access to an outcomes-based agreement for β-thalassemia gene therapy Zynteglo through the Real Endpoints (RE) Marketplace. Zynteglo, which is approved to treat patients with beta-thalassemia who require regular blood transfusions, is priced at $2.8M for a one-time therapy, making it the most expensive treatment in history. Real noted that these plans cover ~16M people in the U.S. Through a single contract, the plans in RE Marketplace can take immediate advantage of bluebird's agreement, which offers rebates of up to 80% if treatment with Zynteglo does not enable a patient to achieve and maintain transfusion independence in two years following therapy, Real said in an Oct. 4 press release. "The plans in RE Marketplace are thrilled to be able to easily access bluebird’s innovative risk-sharing agreement, which speeds the delivery of both clinical and economic innovations," said Real's Chief Clinical Officer Jane Barlow. BLUE +2.77% to $6.30 premarketSeeking Alpha • Sep 26
Bluebird bio names interim finance chief
Gene therapy developer bluebird bio, Inc. (NASDAQ:BLUE) has named Katherine Breedis, formerly the Chief Financial Officer Consultant at Danforth Advisors, as the company’s interim Chief Financial Officer replacing the outgoing CFO Jason Cole. Ms. Breedis has also been named as BLUE’s principal financial officer and principal accounting officer, and her appointments will take effect on Oct. 14 when Mr. Cole departs. Ms. Breedis, who has worked as a CFO consultant for Danforth since Jul. 2021, served as a consultant to BLUE after the company struck a consulting agreement with the advisory firm in May. Mr. Cole’s departure came less than a month after the FDA approved BLUE’s β-thalassemia therapy Zynteglo in August, making it the priciest treatment in history at the time.Seeking Alpha • Sep 19
Bluebird bio jumps 17% on FDA approval of new gene therapy
The commercial-stage biotech bluebird bio, Inc. (NASDAQ:BLUE) added ~17% pre-market Monday after the company announced the FDA approval of its gene therapy Skysona to address the impact of a rare neurodegenerative disease called cerebral adrenoleukodystrophy (CALD). According to the late Friday press release, the drug, also known as elivaldogene autotemcel (eli-cel), will be indicated in the U.S. to slow the progression of neurologic dysfunction in boys aged 4-17 with early, active CALD. With the FDA approving Skysona under the agency’s accelerated approval pathway, BLUE has agreed to deliver long-term clinical data on the treatment to the regulator, including data from an ongoing long-term follow-up study and commercially treated patients. The company expects the drug to be commercially available by the end of 2022 at a list price of $3.0M. Concurrently, BLUE confirmed that the FDA had lifted the clinical hold on the eli-cel development program. In August, Cambridge, Massachusetts-based biotech won FDA approval for another gene therapy known as Zynteglo for β-thalassemia which it priced at $2.8M.Seeking Alpha • Sep 12
bluebird bio' chief strategy and financial officer to depart
Jason Cole, chief strategy and financial officer of bluebird bio (NASDAQ:BLUE), plans to leave the firm, effective Oct 14, 2022, to pursue new career opportunities. Mr. Cole spent 8.5 years at bluebird, serving in multiple roles including general counsel/chief legal officer, chief operating & legal officer and chief business officer. He took the chief strategy and financial officer role in Mar 2022, leading changes to stabilize the firm's financial position and strengthen its balance sheet. bluebird (BLUE) has initiated an external search for its next CFO. In the meantime, Katherine Breedis, an experienced business and financial executive from Danforth Advisors, is expected to serve as interim CFO. Cole is expected to continue to consult with the company on corporate strategy through April 2023.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2027 | 277 | N/A | N/A | N/A | 1 |
| 12/31/2026 | 225 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 227 | -150 | N/A | N/A | 4 |
| 3/31/2025 | 104 | -200 | -230 | -229 | N/A |
| 12/31/2024 | 84 | -241 | -263 | -260 | N/A |
| 9/30/2024 | 53 | -293 | -271 | -264 | N/A |
| 6/30/2024 | 55 | -319 | -254 | -245 | N/A |
| 3/31/2024 | 46 | -301 | -248 | -238 | N/A |
| 12/31/2023 | 29 | -212 | -244 | -235 | N/A |
| 9/30/2023 | 22 | -63 | -209 | -200 | N/A |
| 6/30/2023 | 9 | -52 | -236 | -227 | N/A |
| 3/31/2023 | 4 | -89 | -276 | -262 | N/A |
| 12/31/2022 | 4 | -230 | -329 | -316 | N/A |
| 9/30/2022 | 5 | -431 | -447 | -436 | N/A |
| 6/30/2022 | 6 | -507 | -525 | -506 | N/A |
| 3/31/2022 | 5 | -563 | -574 | -558 | N/A |
| 12/31/2021 | 4 | -563 | -659 | -636 | N/A |
| 9/30/2021 | -238 | -573 | -680 | -651 | N/A |
| 6/30/2021 | -220 | -614 | -678 | -653 | N/A |
| 3/31/2021 | -21 | -480 | -493 | -468 | N/A |
| 12/31/2020 | N/A | -561 | -499 | -470 | N/A |
| 9/30/2020 | 250 | -642 | -509 | -474 | N/A |
| 6/30/2020 | 240 | -653 | -493 | -439 | N/A |
| 3/31/2020 | 54 | -828 | -684 | -616 | N/A |
| 12/31/2019 | N/A | -555 | -641 | -564 | N/A |
| 9/30/2019 | 54 | -715 | -611 | -535 | N/A |
| 6/30/2019 | 57 | -655 | -569 | -496 | N/A |
| 3/31/2019 | 51 | -605 | -526 | -459 | N/A |
| 12/31/2018 | 55 | -556 | N/A | -413 | N/A |
| 9/30/2018 | 40 | -524 | N/A | -379 | N/A |
| 6/30/2018 | 36 | -457 | N/A | -361 | N/A |
| 3/31/2018 | 45 | -382 | N/A | -314 | N/A |
| 12/31/2017 | 35 | -336 | N/A | -281 | N/A |
| 9/30/2017 | 33 | -290 | N/A | -254 | N/A |
| 6/30/2017 | 27 | -288 | N/A | -237 | N/A |
| 3/31/2017 | 11 | -276 | N/A | -228 | N/A |
| 12/31/2016 | 6 | -264 | N/A | -190 | N/A |
| 9/30/2016 | 6 | -239 | N/A | -154 | N/A |
| 6/30/2016 | 6 | -205 | N/A | -143 | N/A |
| 3/31/2016 | 9 | -198 | N/A | -111 | N/A |
| 12/31/2015 | 14 | -167 | N/A | -98 | N/A |
| 9/30/2015 | 19 | -139 | N/A | -81 | N/A |
| 6/30/2015 | 24 | -113 | N/A | -73 | N/A |
| 3/31/2015 | 25 | -63 | N/A | -72 | N/A |
| 12/31/2014 | 25 | -49 | N/A | -60 | N/A |
| 9/30/2014 | 25 | -37 | N/A | -49 | N/A |
| 6/30/2014 | 25 | -26 | N/A | -38 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de BLUE es superior a la tasa de ahorro (2.9%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de BLUE crezcan más rápidamente que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de BLUE crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (21.9% al año) de BLUE crezcan más rápidamente que los del mercado US (11.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (21.9% al año) de BLUE crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BLUE se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2025/05/30 07:12 |
| Precio de las acciones al final del día | 2025/05/30 00:00 |
| Beneficios | 2025/03/31 |
| Ingresos anuales | 2024/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
bluebird bio, Inc. está cubierta por 21 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Zhiqiang Shu | Berenberg |
| Vincent Chen | Bernstein |
| Matthew Luchini | BMO Capital Markets Equity Research |